METHOD FOR PREDICTION OF RISK OF SECONDARY OBLITERATION OF LACRIMAL DUCTS IN PATIENTS AFTER RADIOIODINE THERAPY Russian patent published in 2025 - IPC A61B5/107 G01T1/164 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to nuclear medicine, endocrinology, ophthalmology and radiology, and can be used to determine a risk group of secondary obliteration of the lacrimal ducts in patients after radioiodine therapy for thyroid cancer. Method for predicting the risk of secondary obliteration of the lacrimal ducts in patients after radioiodine therapy involves determining a complex of indicators: age and sex of the patient, presence of menopause for women, presence of involuntary lachrymation at the time of the study, the introduction of the recombinant human thyroid-stimulating hormone to the patient before the study, value of total therapeutic activity of the introduced radiopharmaceutical during radioiodine therapy; performing scintigraphic examination of the patient with the introduction of the radiopharmaceutical, obtaining a direct projection of the scintigraphic image of the head and neck of patient for 72 hours. After the introduction of the radiopharmaceutical, the radiopharmaceutical accumulation areas corresponding to the lachrymal passages are detected on the image, followed by the determination of the radiopharmaceutical accumulation intensity in these areas corresponding to the lachrymal passages, from which the radiopharmaceutical accumulation index is calculated. Derived values are evaluated in points, the sum of which is used to predict a high, medium or low risk of secondary obliteration of the lacrimal ducts after radioiodine therapy.

EFFECT: method enables high-accuracy detection of patients from the risk group of obliteration of the lacrimal ducts due to the value of the radiopharmaceutical accumulation index.

3 cl, 16 dwg, 1 tbl, 4 ex